Syndax Pharmaceuticals (NASDAQ: SNDX) presented data on its menin inhibitor Revuforj (revumenib) at the American Society of Clinical Oncology 2026 Annual Meeting in Chicago. The company highlighted results from patients who received the drug as maintenance therapy following stem cell transplantation.

A pooled analysis examined 24 patients with acute leukemia who resumed revumenib after hematopoietic stem cell transplant. The cohort included 13 adults and 11 children with KMT2A-rearranged, NPM1-mutated, or NUP98-rearranged acute leukemia. Patients had received a median of three prior lines of therapy, with 54% having undergone prior transplant.

The study reported a 2-year overall survival rate of 90% among patients who received revumenib post-transplant, compared to a historical benchmark of 51% for similar patients treated before revumenib became available. The median time to initiate revumenib after transplant was 82 days, with a median treatment duration of 10 months.

Cumulative relapse rates at one year were 0% for patients transplanted in first complete remission and 17% for those in second complete remission or beyond. Historical rates for comparable patients were 12% and 40%, respectively.

The most common adverse event was thrombocytopenia, leading to dose modification in 46% of patients and discontinuation in 13%. The company also presented pharmacokinetic data showing revumenib can be administered with gastric acid reducing agents without reduced efficacy.

Revuforj is FDA-approved for patients one year and older with relapsed or refractory acute leukemia with KMT2A translocation or acute myeloid leukemia with susceptible NPM1 mutation who have no satisfactory alternative treatment options.